Trends in diabetes treatment in Canadians, 1994-2004

Chronic Diseases in Canada

Volumn 30, Issue 3, 2010, Pages 107-111

  Neutel, C I ^a   Campbell, N R ^b   Morrison, H I ^a,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Clinical practice guidelines; Diabetes management; Lifestyle modifications; NPHS survey; Obesity; Oral antidiabetic agents

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ADULT; AGED; ARTICLE; CANADA; DIET; FEMALE; FORECASTING; HEALTH SURVEY; HOSPITALIZATION; HUMAN; LIFESTYLE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; PATIENT CARE; PRACTICE GUIDELINE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; DIABETES MELLITUS, TYPE 2; SEVERITY OF ILLNESS INDEX; TRENDS;

ADMINISTRATION, ORAL; ADULT; AGED; CANADA; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; FORECASTING; HEALTH SURVEYS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; LIFE STYLE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; PATIENT CARE; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77954580548     PISSN: 02288699     EISSN: 14818523     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a populationbased study. Lancet. 2007;369:750-6.
2. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-25.
3. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-9.
4. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765-72.
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91.
6. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, Yale JF, Zinman B, Lillie D. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ. 1998;159 Suppl 8:S1-29.
7. Canadian Diabetes Association Clinical Practice Guideline Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003; 27 Suppl 2:S1-S162.
8. Neutel CI, Campbell NR. Changes in lifestyle after hypertension diagnosis in Canada. Can J Cardiol. 2008;24(3):199-204.
9. Ma J, Lee KV, Staford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48:1-7.
10. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385-411.
11. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007 Dec 12;298(22):2634-43.
12. Campbell NR, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki R. Hypertension in Diabetes: a call to action. Can J Cardiol. 2009; 25:299-308.